<DOC>
	<DOCNO>NCT01924195</DOCNO>
	<brief_summary>Anlotibib ( AL3818 ) kind innovative medicine approve State Food Drug Administration（SFDA:2011L00661） research Jiangsu Chia-tai Tianqing Pharmaceutical Co. , Ltd. Anlotinib kinase inhibitor receptor tyrosine multi-targets , especially VEGFR2、VEGFR3、PDGFRβ c-Kit . It obvious resistance new angiogenesis . The trial explore Anlotinib effectiveness safety andvanced non-small cell lung cancer fail two line chemotherapy</brief_summary>
	<brief_title>Phase II Study Anlotinib Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1. pathology diagnose advanced NSCL measurable lesion ; 2 . Have fail 2 line chemotherapy ; 3 . 1870years , ECOG PS:02 , Life expectancy 3 month ; 4 . Other cytotoxic drug , radiation therapy , surgery≥4 week ; 5. main organ function normal ; 6. must agree take contraceptive measure study within 6 month end . 1 . SCLC ( include mixed NSCLC ) ; 2. central cavity Squamous cell carcinoma hemoptysis NSCLC ; 3. patient fail use antitumor angiogenesis therapy ; 4. patient many influence factor toward oral medication ; 5 . Brain metastasis patient accompany symptoms symptom control less two month ; 6. patient severe fail controlled disease , include : suboptimal blood pressure control ; suffer myocardial ischemia grade I myocardial infarction , arrhythmias Class I heart failure ; activity failure control severe infection ; liver disease cirrhosis , decompensated liver disease , chronic active hepatitis ; poorly control diabetes ( FBG ) &gt; 10mmol/L ) ; urine protein≥++ , etc . 7. patient fail heal wound fracture Longterm ; 8 . 4 week enrollment , patient appear NCI CTC AE grade &gt; 1 pulmonary hemorrhage ; 4 week enrollment , patient appear NCI CTC AE grade &gt; 2 part bleed ; patient tendency bleed ( eg active peptic ulcer ) receive thrombolytic anticoagulant therapy warfarin , heparin analogue ; 9. patient occur venous thromboembolic event within 6 month ; 10. patient HIVpositive organ transplantation ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>lung</keyword>
	<keyword>Anlotinib</keyword>
	<keyword>AL3818</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Cancer</keyword>
</DOC>